Amylin based therapies are emerging as promising obesity medications. Eloralintide is a novel, selective amylin receptor agonist in development for weight management, type 2 diabetes and more! Eloralintide, a selective amylin receptor agonist Amylin Receptor 3 (AMY3R) CRE Luciferase Reporter HEK293 Cell Line GLP 1 83544 PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar In early studies, a new drug under investigation called eloralintide helped some adults lose nearly 50 pounds in under a year and it's not a GLP 1: https: bit.ly 43nPJnS